Nymox Announces Date for Fexapotide Filing
May 06 2021 - 1:30PM
Nymox Pharmaceutical Corporation (NASDAQ: NYMX) (the “Company”) is
pleased to announce that it will be filing for marketing approval
of Fexapotide Triflutate for BPH before the end of the summer, on
or before 15 September 2021.
CEO Dr. Paul Averback said, "The Company will
file on or before September 15. We hope but cannot be certain that
the date may be before September. Company management will
communicate updates where appropriate."
About Nymox Pharmaceutical Corporation
Nymox Pharmaceutical Corporation specializes in
the research and development of therapeutics and diagnostics, with
a particular emphasis on products targeted for the unmet needs of
the rapidly aging male population in developed economies. The
Company’s lead drug candidate for benign prostatic hyperplasia
(BPH), Fexapotide Triflutate (FT), has completed Phase 3
development in more than 70 clinical centers in the United States,
involving more than 1700 patients during the entire clinical
development program.
For more information please contact
info@nymox.com or 800-936-9669.
Forward Looking Statements
To the extent that statements contained in this
press release are not descriptions of historical facts regarding
Nymox, they are forward-looking statements reflecting the current
beliefs and expectations of management made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995, including statements regarding the need for new options to
treat BPH and prostate cancer, the potential of Fexapotide to treat
BPH and prostate cancer and the estimated timing of further
developments for Fexapotide. Such forward-looking statements
involve substantial risks and uncertainties that could cause our
clinical development program, future results, performance or
achievements to differ significantly from those expressed or
implied by the forward-looking statements. Such risks and
uncertainties include, among others, the uncertainties inherent in
the clinical drug development process, including the regulatory
approval process, the timing of Nymox's regulatory filings, Nymox's
substantial dependence on Fexapotide, Nymox's commercialization
plans and efforts and other matters that could affect the
availability or commercial potential of Fexapotide. Nymox
undertakes no obligation to update or revise any forward looking
statements. For a further description of the risks and
uncertainties that could cause actual results to differ from those
expressed in these forward-looking statements, as well as risks
relating to the business of Nymox in general, see Nymox's current
and future reports filed with the U.S. Securities and Exchange
Commission, including its Annual Report on Form 20-F for the year
ended December 31, 2020, and its Quarterly Reports.
For Further Information
Contact: Randall
Lanham Nymox
Pharmaceutical Corporation 1-800-93NYMOX www.nymox.com
Nymox Pharmaceutical (NASDAQ:NYMX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Nymox Pharmaceutical (NASDAQ:NYMX)
Historical Stock Chart
From Sep 2023 to Sep 2024